RU2013108256A - Дисперсии цитрата разагилина - Google Patents
Дисперсии цитрата разагилина Download PDFInfo
- Publication number
- RU2013108256A RU2013108256A RU2013108256/15A RU2013108256A RU2013108256A RU 2013108256 A RU2013108256 A RU 2013108256A RU 2013108256/15 A RU2013108256/15 A RU 2013108256/15A RU 2013108256 A RU2013108256 A RU 2013108256A RU 2013108256 A RU2013108256 A RU 2013108256A
- Authority
- RU
- Russia
- Prior art keywords
- rasagiline
- solid dispersion
- solvent
- pharmaceutical excipient
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Psychology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40036910P | 2010-07-27 | 2010-07-27 | |
| US61/400,369 | 2010-07-27 | ||
| PCT/US2011/045569 WO2012015946A1 (en) | 2010-07-27 | 2011-07-27 | Dispersion of rasagiline citrate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013108256A true RU2013108256A (ru) | 2014-09-10 |
Family
ID=45530490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013108256/15A RU2013108256A (ru) | 2010-07-27 | 2011-07-27 | Дисперсии цитрата разагилина |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8691872B2 (enExample) |
| EP (1) | EP2598136A4 (enExample) |
| JP (1) | JP2013537530A (enExample) |
| AU (1) | AU2011282716A1 (enExample) |
| CA (1) | CA2806737A1 (enExample) |
| RU (1) | RU2013108256A (enExample) |
| WO (1) | WO2012015946A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8809310B2 (en) * | 2006-02-21 | 2014-08-19 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of multiple system atrophy |
| WO2007117431A2 (en) | 2006-04-03 | 2007-10-18 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of restless legs syndrome |
| CN101557706B (zh) * | 2006-12-14 | 2013-08-07 | 泰华制药工业有限公司 | 雷沙吉兰碱结晶固体 |
| EP1987816A1 (de) * | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff |
| CA2711817A1 (en) * | 2008-01-11 | 2009-07-16 | Teva Pharmaceutical Industries Ltd. | Rasagiline formulations, their preparation and use |
| WO2009151594A1 (en) * | 2008-06-10 | 2009-12-17 | Teva Pharmaceutical Industries, Ltd. | Rasagiline soft gelatin capsules |
| PT2451771E (pt) | 2009-07-09 | 2014-09-19 | Ratiopharm Gmbh | Sais de rasagilina e suas preparações farmacêuticas |
| AU2010304755A1 (en) * | 2009-10-09 | 2012-05-24 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of Progressive Supranuclear Palsy |
| CA2785501A1 (en) * | 2009-12-22 | 2011-07-21 | Teva Pharmaceutical Industries Ltd. | 3-keto-n-propargyl-1-aminoindan |
| EP2598136A4 (en) | 2010-07-27 | 2015-03-25 | Teva Pharma | DISPERSIONS OF RASAGILINE CITRATE |
| RU2587330C2 (ru) | 2010-07-27 | 2016-06-20 | Тева Фармасьютикал Индастриз Лтд. | Применение разагилина для лечения обонятельной дисфункции |
| EA201490760A1 (ru) | 2011-10-10 | 2014-09-30 | Тева Фармасьютикал Индастриз Лтд. | R(+)-n-метилпропаргиламиноиндан |
| EA201490761A1 (ru) | 2011-10-10 | 2014-11-28 | Тева Фармасьютикал Индастриз Лтд. | R(+)-n-формилпропаргиламиноиндан |
| AR092168A1 (es) | 2012-08-17 | 2015-03-25 | Teva Pharma | Formulaciones parenterales de rasagilina |
| CN115400087B (zh) | 2018-11-16 | 2023-10-20 | 江苏恒瑞医药股份有限公司 | 一种包含parp抑制剂的药物组合物 |
| WO2022162612A1 (en) | 2021-01-30 | 2022-08-04 | Intas Pharmaceuticals Ltd. | An orodispersible pharmaceutical solid dosage form of rasagiline |
| EP4035654A1 (en) | 2021-01-30 | 2022-08-03 | Intas Pharmaceuticals Limited | An orodispersible pharmaceutical solid dosage form of rasagiline |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5744500A (en) | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
| IL92952A (en) | 1990-01-03 | 1994-06-24 | Teva Pharma | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
| IL112819A (en) | 1991-10-16 | 2001-11-25 | Teva Pharma | Fluorinated 1-aminoindan compounds and a process for their preparation |
| IL115357A (en) | 1995-09-20 | 2000-01-31 | Teva Pharma | Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols |
| IL118836A (en) | 1996-07-11 | 2001-01-11 | Teva Pharma | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
| WO1998027055A1 (en) | 1996-12-18 | 1998-06-25 | Teva Pharmaceutical Industries, Ltd. | Aminoindan derivatives |
| US7396860B2 (en) | 2002-11-15 | 2008-07-08 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis |
| AU2004294674B2 (en) * | 2003-12-01 | 2009-02-26 | Recordati Ireland Limited | Pharmaceutical compositions comprising lercanidipine |
| AU2005269416B2 (en) | 2004-07-26 | 2011-07-28 | Teva Pharmaceutical Industries, Ltd. | Pharmaceutical dosage forms including rasagiline |
| ZA200704917B (en) | 2004-11-24 | 2008-11-26 | Teva Pharma | Rasagiline orally disintegrating compositions |
| CA2600011C (en) | 2005-02-23 | 2015-11-10 | Teva Pharmaceutical Industries Ltd. | Rasagiline formulations of improved content uniformity |
| CA2630037C (en) | 2005-11-17 | 2015-03-31 | Teva Pharmaceutical Industries Ltd. | Methods for isolating propargylated aminoindans |
| US7572834B1 (en) | 2005-12-06 | 2009-08-11 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations and processes for their preparation |
| US8809310B2 (en) | 2006-02-21 | 2014-08-19 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of multiple system atrophy |
| CN101032474B (zh) | 2006-03-06 | 2011-02-16 | 重庆医药工业研究院有限责任公司 | 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法 |
| WO2007117431A2 (en) | 2006-04-03 | 2007-10-18 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of restless legs syndrome |
| EP1892233A1 (de) | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | Neue Salze des Wirkstoffs Rasagilin |
| ZA200903904B (en) | 2006-12-14 | 2010-08-25 | Teva Pharma | Tannate salt of rasagiline |
| CN101557706B (zh) | 2006-12-14 | 2013-08-07 | 泰华制药工业有限公司 | 雷沙吉兰碱结晶固体 |
| EP1987816A1 (de) | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff |
| JP2010538067A (ja) | 2007-09-05 | 2010-12-09 | テバ ファーマシューティカル インダストリーズ リミティド | ラサギリンを使用する緑内障の治療方法 |
| US8188149B2 (en) | 2007-09-17 | 2012-05-29 | Teva Pharmaceutical Industries, Ltd. | Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss |
| CA2711817A1 (en) | 2008-01-11 | 2009-07-16 | Teva Pharmaceutical Industries Ltd. | Rasagiline formulations, their preparation and use |
| WO2009151594A1 (en) | 2008-06-10 | 2009-12-17 | Teva Pharmaceutical Industries, Ltd. | Rasagiline soft gelatin capsules |
| US20090312436A1 (en) | 2008-06-13 | 2009-12-17 | Ruth Levy | Rasagiline for parkinson's disease modification |
| AU2009260733B2 (en) | 2008-06-19 | 2015-01-29 | Teva Pharmaceutical Industries, Ltd. | Process for purifying rasagiline base |
| JP2011524907A (ja) | 2008-06-19 | 2011-09-08 | テバ ファーマシューティカル インダストリーズ リミティド | 固体ラサギリン塩基を調製および乾燥する方法 |
| DE102008064061A1 (de) * | 2008-12-19 | 2010-06-24 | Ratiopharm Gmbh | Feste Zusammensetzung mit dem Wirkstoff Rasagilin |
| EP2218444A3 (en) * | 2009-01-23 | 2010-08-25 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline formulation |
| US8080584B2 (en) | 2009-01-23 | 2011-12-20 | Teva Pharmaceuticals Industries, Ltd. | Delayed release rasagiline citrate formulation |
| PT2451771E (pt) | 2009-07-09 | 2014-09-19 | Ratiopharm Gmbh | Sais de rasagilina e suas preparações farmacêuticas |
| AU2010304755A1 (en) | 2009-10-09 | 2012-05-24 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of Progressive Supranuclear Palsy |
| CA2785501A1 (en) | 2009-12-22 | 2011-07-21 | Teva Pharmaceutical Industries Ltd. | 3-keto-n-propargyl-1-aminoindan |
| RU2587330C2 (ru) | 2010-07-27 | 2016-06-20 | Тева Фармасьютикал Индастриз Лтд. | Применение разагилина для лечения обонятельной дисфункции |
| EP2598136A4 (en) | 2010-07-27 | 2015-03-25 | Teva Pharma | DISPERSIONS OF RASAGILINE CITRATE |
| WO2012058219A2 (en) | 2010-10-26 | 2012-05-03 | Teva Pharmaceutical Industries Ltd. | Deuterium enriched rasagiline |
| EA201490760A1 (ru) | 2011-10-10 | 2014-09-30 | Тева Фармасьютикал Индастриз Лтд. | R(+)-n-метилпропаргиламиноиндан |
| BR112014008550A2 (pt) | 2011-10-10 | 2017-04-18 | Teva Pharma | citramida rasagilina |
| EA201490761A1 (ru) | 2011-10-10 | 2014-11-28 | Тева Фармасьютикал Индастриз Лтд. | R(+)-n-формилпропаргиламиноиндан |
-
2011
- 2011-07-27 EP EP11813128.3A patent/EP2598136A4/en not_active Withdrawn
- 2011-07-27 WO PCT/US2011/045569 patent/WO2012015946A1/en not_active Ceased
- 2011-07-27 RU RU2013108256/15A patent/RU2013108256A/ru not_active Application Discontinuation
- 2011-07-27 JP JP2013521947A patent/JP2013537530A/ja not_active Withdrawn
- 2011-07-27 CA CA2806737A patent/CA2806737A1/en not_active Abandoned
- 2011-07-27 US US13/192,082 patent/US8691872B2/en not_active Expired - Fee Related
- 2011-07-27 AU AU2011282716A patent/AU2011282716A1/en not_active Abandoned
-
2014
- 2014-03-10 US US14/203,209 patent/US20140194510A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2598136A1 (en) | 2013-06-05 |
| EP2598136A4 (en) | 2015-03-25 |
| JP2013537530A (ja) | 2013-10-03 |
| WO2012015946A8 (en) | 2013-01-31 |
| AU2011282716A1 (en) | 2013-03-14 |
| US20140194510A1 (en) | 2014-07-10 |
| CA2806737A1 (en) | 2012-02-02 |
| US8691872B2 (en) | 2014-04-08 |
| WO2012015946A1 (en) | 2012-02-02 |
| US20120059058A1 (en) | 2012-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013108256A (ru) | Дисперсии цитрата разагилина | |
| JP2013537530A5 (enExample) | ||
| JP2009530415A5 (enExample) | ||
| RU2017106795A (ru) | Новые составы ингибитора тирозинкиназы брутона | |
| JP2012236837A5 (enExample) | ||
| JP2009530416A5 (enExample) | ||
| HRP20221355T1 (hr) | Liofilizirani pripravak citotoksičnih dipeptida | |
| CN102453024B (zh) | 一种尼罗替尼盐酸盐晶型及其制备方法 | |
| RU2016136697A (ru) | Комплексы сиролимуса и его производных, способ их получения и фармацевтические композиции, содержащие указанные комплексы | |
| KR101895962B1 (ko) | 알리사르탄 이소프록실 고체 분산체 및 이를 포함하는 약제학적 조성물 | |
| JP2017505313A5 (enExample) | ||
| CN102178642A (zh) | 一种替米沙坦固体分散体及其制备方法 | |
| JP7733160B2 (ja) | カンナビジオール懸濁液を含有する可溶性マイクロニードル及びその調製方法 | |
| CN108186597A (zh) | 一种鲁比前列酮固体分散体及其制备方法 | |
| CN102871994B (zh) | 氟比洛芬对乙酰氨基酚酯环糊精包合物及其制备方法 | |
| CN102977039B (zh) | 6-氟-3-羟基-2-吡嗪甲酰胺α晶型及其制备方法 | |
| CN111249226A (zh) | 一种七叶皂苷可注射水凝胶及其制备方法和应用 | |
| CN105412027A (zh) | 一种盐酸决奈达隆片剂的制备方法 | |
| CN106619503B (zh) | 一种大黄酸酰胺类衍生物纳米混悬剂及其制备方法和应用 | |
| CN112972380B (zh) | 一种多功能新型给药系统制剂的制备方法及应用 | |
| JPWO2014175303A1 (ja) | レボノルゲストレルの結晶多形α及びその製造方法 | |
| CN103494809B (zh) | 一种包含罗匹尼罗的组合物的制备方法 | |
| CN105434378B (zh) | 美索舒利分散片及其制备方法 | |
| Li et al. | Design and Development of Fiber Patch to Prevent Reperfusion Injury and Provide Thermal Stimulation for Treating Severe Frostbite | |
| CN102178722A (zh) | 一种柿叶总黄酮缓释微丸及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160122 |